Dr. Soumya Basu | Molecular Biology | Best Faculty Award
Dr. Soumya Basu, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, India.
π Early Academic Pursuits
Dr. Soumya Basu began her academic journey with a B.Sc. (Hons.) in Physics, Chemistry, and Mathematics from the University of Burdwan in 2001. She later pursued an M.Sc. in Microbiology from the University of Kalyani in 2003, demonstrating her keen interest in the biological sciences. Her commitment to advancing her expertise led her to obtain a Ph.D. in Life Sciences from Jadavpur University in 2012. She also expanded her interdisciplinary knowledge by completing an Advanced Diploma in Medical Writing and Regulatory Affairs in 2014 and an Advanced PG Course in Artificial Intelligence and Machine Learning from the University of Texas at Austin in 2021.
πΌ Professional Endeavors
Dr. Basu has an extensive academic career spanning 18+ years, currently serving as an Associate Professor and Principal Investigator at the Cancer and Translational Research Centre, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Pune. Previously, she worked as an Assistant Professor at the same institution and held research positions at renowned organizations such as ACTREC, Tata Memorial Center, CNCI, Jadavpur University, and the University of Calcutta. Her academic journey also includes an early teaching role as a Lecturer at Kulti College, Burdwan.
π¬ Contributions and Research Focus On Molecular Biology
s Dr. Basu’s research primarily revolves around cancer therapeutics, molecular biology, and artificial intelligence in life sciences. Her key research areas include:
- Designing natural product analogs for lung carcinoma treatment
- Targeting metastatic lymph nodes in breast cancer using novel drug delivery systems
- Investigating small molecules and Exosomal-miRNA as potential cancer therapeutics
- Exploring non-coding RNAs as drug targets in oncology
- Utilizing systems biology for pathway analysis in different cancer types
π Impact and Influence
Dr. Basu has significantly contributed to the field of translational cancer research, bridging laboratory discoveries with clinical applications. Her work in molecular docking, drug synthesis, and bioinformatics has led to innovative breakthroughs in targeted cancer therapies. She has mentored several Ph.D. students and actively collaborates with national and international research institutes.
π Academic Citations
Dr. Basu has an H-index of 14 and over 550 citations, reflecting the impact and recognition of her research within the scientific community. Her publications in high-impact journals and book chapters have been widely referenced by researchers in cancer biology, molecular medicine, and bioinformatics.
π Awards and Honors
Dr. Basu has received numerous grants and accolades, including:
- DST-SERB Early Career Research Award
- Multiple intramural grants for pioneering cancer research projects
- ICMR Senior Research Fellowship
π Technical Expertise
Dr. Basu is proficient in:
- Animal handling and in vivo tumor modeling
- Fluorescence microscopy, live-cell imaging, and bioluminescence techniques
- Cell culture, flow cytometry, and apoptosis assays
- Molecular biology techniques such as PCR, cloning, and sequencing
- Computational biology, including AI/ML applications in drug discovery
π Legacy and Future Contributions
With her vast experience in oncology research, AI applications in life sciences, and molecular medicine, Dr. Basu aims to further pioneer innovative cancer treatments. She continues to lead projects focused on targeted drug delivery, personalized medicine, and bioinformatics-driven drug discovery.
Publications Top Notes
1οΈβ£ Synthesis, Spectroscopic Characterization, X-ray Powder Structure Analysis, DFT Study & In Vitro Anticancer Activity of N-(2-methoxyphenyl)-3-methoxysalicylaldimine
π Journal of Molecular Structure | π’ Citations: 69 | π
Year: 2009
2οΈβ£ Targeting Mitochondrial Cell Death Pathway to Overcome Drug Resistance with a Newly Developed Iron Chelate
π PLoS One | π’ Citations: 52 | π
Year: 2010
3οΈβ£ Probing Intermolecular Interactions & Binding Stability of Kaempferol, Quercetin, and Resveratrol Derivatives with PPAR-Ξ³
π Journal of Biomolecular Structure and Dynamics | π’ Citations: 43 | π
Year: 2022
4οΈβ£ Use of BRET to Study ProteinβProtein Interactions in Vitro and In Vivo
π The Nuclear Receptor Superfamily: Methods and Protocols | π’ Citations: 39 | π
Year: 2016
5οΈβ£ Redox Active Copper Chelate Overcomes Multidrug Resistance in T-Lymphoblastic Leukemia Cell by Triggering Apoptosis
π Molecular BioSystems | π’ Citations: 35 | π
Year: 2011
6οΈβ£ PPAR-Ξ³ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
π Cells | π’ Citations: 30 | π
Year: 2022
7οΈβ£ Drug RepurposingβAn Emerging Strategy in Cancer Therapeutics
π Naunyn Schmiedebergs Arch Pharmacol | π’ Citations: 30 | π
Year: 2022
8οΈβ£ Exploring Conformational Changes of PPAR-Ξ³ Complexed with Novel Kaempferol, Quercetin, & Resveratrol Derivatives
π Journal of Molecular Modeling | π’ Citations: 26 | π
Year: 2020
9οΈβ£ Induction of Intrinsic & Extrinsic Apoptosis through Oxidative Stress in Drug-Resistant Cancer by a Newly Synthesized Schiff Base Copper Chelate
π Free Radical Research | π’ Citations: 26 | π
Year: 2016
π Targeting the Mitochondrial Pathway to Induce Apoptosis/Necrosis through ROS by a Newly Developed Schiffβs Base
π Biochimie | π’ Citations: 26 | π
Year: 2012